阿奇霉素与头孢西丁治疗盆腔支原体感染的临床效果对比分析

The effect of azithromycin combined cefoxitin in the treatment of pelvic inflammation caused by mycoplasma infection

目的:探讨支原体感染盆腔炎患者应用阿奇霉素治疗的临床效果及安全性。方法:按随机数字表法将我院2012年8月至2014年8月收治的140例支原体感染盆腔炎患者分为对照组和观察组,每组70例。两组患者均在给予盆腔炎2号方的同时联合其他药物治疗,其中对照组联合头孢西丁治疗,观察组联合阿奇霉素治疗,比较两组患者的临床疗效和不良反应发生率。结果:观察组痊愈51例,显效11例,有效6例,无效2例,治疗总有效率为97.14%;对照组痊愈32例,显效13例,有效12例,无效13例,治疗总有效率为81.43%,组间比较差异具有统计学意义(P<0.05)。观察组的子宫血流动力学指标均高于对照组,比较差异具有统计学意义(P<0.05)。观察组的不良反应发生率为7.14%;对照组为28.57%,组间比较差异具有统计学意义(P<0.05)。结论:支原体感染盆腔炎患者应用阿奇霉素治疗的临床疗效较好,不良反应也较少,具有临床推广价值。

Objectives：To investigate the clinical effect and safety of azithromycin combined cefoxitin in treating pelvic inflammation patients with mycoplasma infection.Methods：1 40 pelvic inflammation patients with mycoplasma infection in our hospital from August 201 2 to August 201 4 were selected and randomly divided into con-trol group and observation group,70 cases in each group.Besides the second therapy for pelvic inflammation,the control group jointly received cefoxitin and the observation group received azithromycin for treatment.The clinical efficacy and incidence rate of adverse reaction in the two groups were compared.Results：In the observation group, there were 51 cases cured,1 1 cases markedly effective,6 cases effective,and 2 cases invalid,the total efficiency of treatment being 97.1 4%;in the control group there were 32 cases cured,1 3 cases markedly effective,1 2 cases ef-fective and 1 3 cases invalid,the total efficiency of treatment being 81 .43%,with statistically significant differences between the two groups （P 〈0.05）.The uterine hemodynamics indexes in the observation group were higher than those in the control group,with statistically significant difference （P 〈0.05）;the incidence rate of adverse reaction in the observation group and control group was 7.1 4% and 28.57% respectively,with statistically significant differ-ence （P 〈0.05）.Conclusion：Azithromycin is of better clinical effect in treating pelvic inflammation patients with mycoplasma infection,with less adverse reactions.